Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02667327 · ClinicalTrials.gov registry record · Phase 3
A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer
A Phase 3 study, sponsored by Xequel Bio.
- Terminated
- Registry status
- Phase 3
- Development phase
- 124
- Enrollment target
NCT02667327 is a Phase 3 study that was terminated before completion, run by Xequel Bio. The registered enrollment target is 124 participants.
The verdict
NCT02667327, a Phase 3 study, was terminated before completion, sponsored by Xequel Bio.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 124 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Granexin gel is safe and effective in the treatment of diabetic foot ulcers.
Interventions
- OTHER Vehicle gel
- DRUG Granexin gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2018-11-21 |
| Est. Completion | 2020-05-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02667327
The ClinicalTrials.gov registry entry for NCT02667327 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xequel Bio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle gel is the first listed.
NCT02667327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02667327 about?
NCT02667327 is a clinical study titled "A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer". The purpose of this study is to determine whether Granexin gel is safe and effective in the treatment of diabetic foot ulcers.
What is the current status of trial NCT02667327?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 124 participants. The study started on 2018-11-21. Estimated completion is 2020-05-27.
What interventions are being tested in trial NCT02667327?
The interventions under investigation include: Vehicle gel (OTHER), Granexin gel (DRUG).
Who is sponsoring clinical trial NCT02667327?
This trial is sponsored by Xequel Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.